Navigation Links
Escalon(R) Reports Fourth Quarter and Fiscal 2009 Results
Date:10/13/2009

further diversify its product line to achieve critical mass in sales and take better advantage of the Company's distribution capabilities, although such partnerships or acquisitions may not occur. The Company has headquarters in Wayne, Pennsylvania and operations in Long Island, New York, New Berlin, Wisconsin, Lawrence, Massachusetts, Dallas, Texas, Waterbury, Connecticut, Miami, Florida, Barrow-in-Furness, U.K. and Le Rheu, France.

Note: This press release contains statements that are considered forward-looking under the Private Securities Litigation Reform Act of 1995, including statements about the Company's future prospects. These statements are based on the Company's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to:

  • implement its growth and marketing strategies, improve upon the operations of the Company business units, including the ability to make acquisitions and the integration of any acquisitions it may undertake, if any, of which there can be no assurance,
  • implement cost reductions,
  • generate cash,
  • identify, finance and enter into business relationships and acquisitions.

Other factors include uncertainties and risks related to:

  • new product development, commercialization, manufacturing and market acceptance of new products,
  • marketing acceptance of existing products in new markets,
  • research and development activities, including failure to demonstrate clinical efficacy,
  • delays by regulatory authorities, scientific and technical advances by the Company or third parties,
  • introduction of competitive products,
  • ability to reduce staffing and other costs and retain benefit of prior reductions
  • third party reimbursement and physician training, and
  • general economic conditions.

    '/>"/>

SOURCE Escalon Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Escalon(R) Announces Going Concern Qualification
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. Tapestry Reports Second Quarter 2007 Results
5. Callisto Reports on Second-Quarter 2007 Milestones
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
10. Biopure Reports on Meeting with the FDA
11. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014  Boehringer Ingelheim today announced that ... for review the New Drug Application (NDA) for ... delivered via the Respimat ® inhaler for ... of airflow obstruction in patients with chronic obstructive ... Tiotropium + olodaterol FDC will not be indicated ...
(Date:8/19/2014)... -- Cardiva Medical, Inc. announced today that it has closed ... 3 private equity financing and a $12.5 million senior ... the proceeds of the Series 3 private equity financing ... VASCADE® Vascular Closure System in the United ... 3 private equity financing was a new investor, Canepa ...
(Date:8/19/2014)... Aug. 19, 2014  Sequence, Inc., an industry leader in ... and medical device manufacturers is opening a third office location ... , as a result of demand by clients to ... opened this month, allows Sequence to better serve new and ... St. Louis office provides Sequence a hub ...
Breaking Medicine Technology:Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2Quality and Compliance Solutions Provider Announces Opening of St. Louis, Missouri Office 2
... FRANCISCO, Calif., June 01, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, ... from ongoing clinical,studies of SNS-595 and SNS-032 at ... being held June 7-10, 2007 in Vienna,Austria. , ... Phase 1 clinical trial of SNS-595 in acute ...
... Zurich, June 1, 2007-Cytos Biotechnology AG is ... presentations of its novel,immunotherapeutic CYT003-QbG10 to treat ... were obtained,and will be presented in different ... Academy of Allergology and Clinical Immunology,(EAACI), taking ...
Cached Medicine Technology:Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 2Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 3CYT003-QbG10 to treat allergy to be presented at the Congress of,the European Academy of Allergology and Clinical Immunology,(EAACI), June 9-13, 2007 2
(Date:8/20/2014)... August 20, 2014 BuyCheapTicketsToEvents.com is ... wide selection of tickets to many events. Cheap NHL hockey ... begin in September. , Hockey fans are enthusiastic about their ... tickets for games. Now is the time to acquire 2014 ... in mere months. There will be a great deal of ...
(Date:8/20/2014)... people grow older, they often have difficulty falling asleep ... in the morning. In individuals with Alzheimer,s disease, this ... especially pronounced, often leading to nighttime confusion and wandering. ... Israel Deaconess Medical Center (BIDMC) and the University of ... more fragmented with age. Reported online today in the ...
(Date:8/20/2014)... Mixberry Media announced today its new integrated ... a new source of revenue. , The innovative experience ... a narration of their favorite news and articles using ... Users can now multitask: read/write email, drink coffee, get ... , Mixberry Media’s service converts news and ...
(Date:8/20/2014)... Riverside Health System is pleased to ... its Warsaw Medical Arts team earlier this year, bringing ... is accepting new patients. , Dameron, a 2009 graduate ... residency at the Mountain Area Health Education Center in ... really like the rural aspect of [Tappahannock],” Dameron said ...
(Date:8/19/2014)... As moms and dads prepare their children to go ... normal routine of dropping their little ones off at daycare ... encourages them to use the opportunity to implement a ... Yarker explains, “Kids have small tummies, short attention spans, and ... food handouts, use snack time as another daily opportunity to ...
Breaking Medicine News(10 mins):Health News:2014 NHL Preseason Tickets Are Among Top Selling Seats at Trusted Provider BuyCheapTicketsToEvents.com 2Health News:Research helps explain why elderly have trouble sleeping 2Health News:Research helps explain why elderly have trouble sleeping 3Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Riverside Warsaw Medical Arts’ Dr. William Dameron Accepting New Patients 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 3
... , NEW YORK, Sept. 21 ... the validity of two Minerva Industries, Inc. patents for mobile ... of new evidence which can show Eli Lilly & Company,s ... counsel. The discovery of this patent validity evidence can impact ...
... , ST. LOUIS, Sept. 21 ... Perrigo Company (Nasdaq: PRGO ) of KV,s first-to-file Paragraph ... Drug Administration for a generic equivalent version of GlaxoSmithKline,s Duac(R) gel. ... transaction, KV will receive $14 million from Perrigo at closing and ...
... WASHINGTON, Sept. 21 /EIN News/ According to the Web site ... the Clinton administration Philip Morris "worked off-the-record with . . . ... have been partly funded by a huge increase in tobacco taxes. ... the term "death panels" used by anti-healthcare reform activists determined to ...
... By 2050, 115 million people may suffer from dementia ... Alzheimer,s disease is accelerating at a rapid pace, and by ... from dementia -- a 10 percent increase since 2005, ... double every 20 years, reaching 65.7 million in 2030 and ...
... , , FORT ... Multicultural Communities Survey sponsored by the LACTAID(R) Brand found that ... or dairy in their diet as a way to manage their ... have lactose intolerance worry the condition keeps them from consuming important ...
... , BALTIMORE, Sept. 21 A new ... the recession is contributing to acute, or short-term, physical pain ... Pain Awareness Month, 68 percent of people who experienced acute ... the past year said that the recession caused, increased or ...
Cached Medicine News:Health News:Minerva and Cymbalta Patent Invalidity Evidence Uncovered by Article One Partners Community 2Health News:Minerva and Cymbalta Patent Invalidity Evidence Uncovered by Article One Partners Community 3Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 2Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 3Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 4Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 5Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 6Health News:'Death Panel' Inventor & Critic of Healthcare Reform Betsy McCaughey 'Has Close Ties' to Philip Morris; Healthcare Industry Today Offers Complete Coverage 2Health News:Alzheimer's Soars, Global Focus Needed: Study 2Health News:Alzheimer's Soars, Global Focus Needed: Study 3Health News:New Research Finds Most African American Women with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 2Health News:New Research Finds Most African American Women with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 3Health News:New Research Finds Most African American Women with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 4Health News:Economic Pain Contributing to Acute Physical Pain for Many Americans, New Survey Says 2Health News:Economic Pain Contributing to Acute Physical Pain for Many Americans, New Survey Says 3Health News:Economic Pain Contributing to Acute Physical Pain for Many Americans, New Survey Says 4
Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe....
Bard® Channel Drain...
... Used for stone manipulation ... duct. The nitinol memory wire ... its shape following extreme torsion. ... the likelihood of mucosal damage ...
Used for serial post-operative cholangiography and the placement of a wire guide to facilitate post-operative E.R.C.P. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: